ANTI-FIBROTIC THERAPY MODULATES MORTALITY RISK ASSOCIATED WITH CIRCULATING PLASMA BIOMARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

被引：1
|
作者：
Oldham, Justin
Alqalyoobi, Shehabaldin
Adegunsoye, Ayodeji
Linderholm, Angela
Hrusch, Cara
Pugashetti, Janelle
Boctor, Noelle
Sperling, Anne
Strek, Mary
Noth, Imre
机构：
来源：
CHEST | 2019年 / 156卷 / 04期
关键词：
D O I：
10.1016/j.chest.2019.08.305
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：258A / 259A
页数：2
相关论文
共 50 条
  • [41] Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis.
    Mendoza, Onofre Moran
    Aldhaheri, Sharina
    Mccarthy, Lynda
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [42] Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis
    Adegunsoye, Ayodeji
    Alqalyoobi, Shehabaldin
    Linderholm, Angela
    Bowman, Willis S.
    Lee, Cathryn T.
    Pugashetti, Janelle Vu
    Sarma, Nandini
    Ma, Shwu-Fan
    Haczku, Angela
    Sperling, Anne
    Strek, Mary E.
    Noth, Imre
    Oldham, Justin M.
    [J]. CHEST, 2020, 158 (04) : 1526 - 1534
  • [43] Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function
    Ebina, M.
    Kimura, Y.
    Ohta, H.
    Hisata, S.
    Tamada, T.
    Nukiwa, T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [44] Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis
    Sugino, Keishi
    Shimizu, Hiroshige
    Nakamura, Yasuhiko
    Isshiki, Takuma
    Matsumoto, Keiko
    Homma, Sakae
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 899 - 908
  • [45] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    [J]. PLOS ONE, 2024, 19 (06):
  • [46] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [47] Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
    Ishii, Daisuke
    Kawasaki, Takeshi
    Sato, Hironori
    Tatsumi, Koichiro
    Imamoto, Takuro
    Yoshioka, Keiichiro
    Abe, Mitsuhiro
    Hasegawa, Yoshinori
    Ohara, Osamu
    Suzuki, Takuji
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [48] Mortality Risk of Patients With Idiopathic Pulmonary Fibrosis
    Raimundo, Karina
    Broder, Michael
    Chang, Eunice
    Papoyan, Elya
    Popescu, Ioana
    Reddy, Sheila
    Stauffer, John
    [J]. CHEST, 2016, 150 (04) : 484A - 484A
  • [49] Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing
    Burgess, Andrew
    Goon, Ken
    Brannan, John D.
    Attia, John
    Palazzi, Kerrin
    Oldmeadow, Christopher
    Corte, Tamera J.
    Glaspole, Ian
    Goh, Nicole
    Keir, Gregory
    Allan, Heather
    Chapman, Sally
    Cooper, Wendy
    Ellis, Samantha
    Hopkins, Peter
    Moodley, Yuben
    Reynolds, Paul
    Zappala, Chris
    Macansh, Sacha
    Grainge, Christopher
    [J]. RESPIROLOGY, 2019, 24 (10) : 988 - 995
  • [50] Anti-Fibrotic Effects of Azithromycin in Human Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Compared to Control Fibroblasts
    Funke, M.
    Krempaska, K.
    Schliep, R.
    Knudsen, L.
    Geiser, T. K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
12345